Name | LCB-2853 |
---|---|
Synonyms |
(4-{[1-({[(4-Chlorophenyl)sulfonyl]amino}methyl)cyclopentyl]methyl}phenyl)acetic acid
Benzeneacetic acid, 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl]methyl]- |
Description | LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities. |
---|---|
Related Catalog | |
Target |
TXA2 Receptor |
In Vivo | In dog coronary stenosis, LCB 2853 shows a very high efficacy with ED50 of 7.2 μg/kg. In rat venous thrombosis induced by combination of venous injury and blood stasis, perfused LCB 2853 decreases the weight of thrombi in a dose related manner with ED50 of 220 μg/kg/min[1]. In vivo, both against platelet aggregation and vasoconstriction, LCB 2853 shows an ED50 lower than 1 mg/kg i.v. in rat AA-induced thrombocytopenia or U 46619-induced hypertension (ED50 = 0.25 and 0.16 mg/kg) as well as in AA-induced sudden death in the mouse (ED50 = 0.44 mg/kg). The U 46619-induced bronchoconstriction is blocked after i.v. administration of LCB 2853 (ED50 = 18.4 μg/kg)[2]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 591.9±60.0 °C at 760 mmHg |
Molecular Formula | C21H24ClNO4S |
Molecular Weight | 421.938 |
Flash Point | 311.8±32.9 °C |
Exact Mass | 421.111450 |
LogP | 5.26 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.602 |
Storage condition | 2-8℃ |